Total Value in 2020: $146.36M (178 deals)

Deal title Principal company/nonprofit Partner company/nonprofit Value (US$M) Start date

March

Brigham & Women to evaluate perioperative use of Acelrx's Dsuvia for spine surgery Acelrx Pharmaceuticals Inc. Brigham & Women's Hospital Payment unspecified 3/6/20
UAB to develop Altimmune's AdCOVID against COVID-19 Altimmune Inc. University of Alabama at Birmingham Payment unspecified 3/30/20
Kuur Therapeutics and Baylor College of Medicine to develop cancer therapies using a CAR NK T-cell therapy platform Baylor College of Medicine Kuur Therapeutics Inc. Payment unspecified 3/10/20
Allovir expanded the research and development collaboration with Baylor College of Medicine to use Allovir's technology for the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies including, ALVR-106 to combat SARS-CoV-2 Baylor College of Medicine Allovir Inc. Payment unspecified 3/23/20
Berkeley to form consortium with VUMC for discovery of neutralizing antibodies against COVID-19 and other viruses Berkeley Lights Inc. Vanderbilt University Medical Center, US Payment unspecified 3/25/20
Janssen Pharmaceutical and Beth Israel Deaconess Medical Center to develop a vaccine to treat COVID-19 infection Beth Israel Deaconess Medical Center Janssen Pharmaceuticals Inc. Payment unspecified 3/13/20
CCFV and IMV to conduct preclinical and clinical studies of DPX-COVID-19 for Coronavirus infection Canadian Center for Vaccinology IMV Inc. Payment unspecified 3/18/20
Ideaya Biosciences expanded research collaboration with Cancer Research UK and the University of Manchester to develop small-molecule inhibitors of poly(ADP-ribose) glycohydrolase (PARG) Cancer Research UK and the University of Manchester Ideaya Biosciences Inc. Payment unspecified 3/11/20
Celldex Therapeutics to receive a $1.7M payment related to a 2013 agreement with Rockefeller University to perform manufacturing and development services for broadly neutralizing antibodies against HIV, including clinical-stage candidates 3-BNC-117 and 10-1074 Celldex Therapeutics Inc. Rockefeller University $1.70 3/3/20
Avectas and CCRM to accelerate nonviral cell engineering platform to develop therapies for immune-oncology and gene editing Centre for Commercialization of Regenerative Medicine Avectas Ltd. Payment unspecified 3/3/20
Pluristem and Charite University to develop PLX cell product candidates for COVID-19 Charite Universitaetsmedizin Berlin Pluristem Therapeutics Inc. Payment unspecified 3/12/20
RDIF and GC Khimrar to form a joint venture to develop and manufacture Favipiravir and antiviral drugs against coronavirus infection in Russia Chemrar High Tech Center Russian Direct Investment Fund Payment unspecified 3/26/20
Sihuan Pharmaceutical and Ministry of Science and Technology to conduct clinical research on Favipiravir tablet against COVID-19 Chinese Ministry of Science and Technology Sihuan Pharmaceutical Holdings Group Ltd. Payment unspecified 3/2/20
GARDP to use Daiichi's chemical library to identify the antibacterial compounds for drug resistant infections Daiichi Sankyo Co. Ltd. Global Antibiotic Research and Development Partnership Payment unspecified 3/12/20
Absolute Antibody and Technical University of Denmark to develop engineered recombinant antibodies specific for animal toxins, such as from snake venoms Denmark Technical University Absolute Antibody Payment unspecified 2/20/20
Ridgeback Biotherapeutics to develop Drug Innovations at Emory's EIDD-2801 against COVID-19 treatment Drug Innovations at Emory LLC Ridgeback Biotherapeutics LP Payment unspecified 3/19/20
Diverse Biotech and Duke University Medical Center to evaluate the efficacy of cannabidiol compounds in glioblastoma animal models Duke University Medical Center Diverse Biotech Inc. Payment unspecified 3/30/20
Duke-NUS Medical School and Arcturus Therapeutics to develop Coronavirus vaccine using STARR technology Duke-NUS Medical School Arcturus Therapeutics Inc. Payment unspecified 3/4/20
Wuxi Biologics to evaluate Dyadic's C1 gene expression platform for vaccine and drug development and manufacturing Dyadic International Inc. Wuxi Biologics Payment unspecified 3/30/20
Anabios and FDA to study adult human primary cardiomyocytes as standards for reference of gene expression and localization of functional proteins Food and Drug Adminstration Anabios Corp. Payment unspecified 3/10/20
Fred Hutchinson to evaluate Lonza's Cocoon platform for manufacturing of cell therapies against cancer Fred Hutchinson Cancer Research Center Lonza Group AG Payment unspecified 3/9/20
Ziphius Therapeutics to use Ghent University's mRNA platform to develop ZIP-1642 for COVID-19 Ghent University Ziphius Therapeutics NV Payment unspecified 3/23/20
Astellas Pharma and Gifu University to develop bacterial infection treatments using engineered bacteriophages Gifu University Astellas Pharma Inc. Payment unspecified 3/18/20
Grifols and BARDA to develop first plasma derived hyperimmune globulin treatment for COVID-19 Grifols SA U.S. Biomedical Advanced Research and Development Authority Payment unspecified 3/25/20
Demelle to use Moffitt Cancer Center's technology to develop DM-3001 against pancreatic cancer worldwide H Lee Moffitt Cancer Center and Research Institute Demelle Oncopharma LLC Payment unspecified 3/4/20
Themis to conduct research and identify a coronavirus vaccine using Institut Pasteur's vaccine technology Institut Pasteur Themis Bioscience GmbH Payment unspecified 3/20/20
ISB and Isoplexis to collaborate to study COVID-19 using single cell functional proteomics platform Institute For Systems Biology Isoplexis Corp. Payment unspecified 3/24/20
Institute of Materia Medica and Cyclica to discover and design multi-targeted antiviral drug candidates using Matchmaker technology for COVID-19 Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College Cyclica Inc. Payment unspecified 3/5/20
Junshi Biosciences and IMCAS to jointly develop neutralizing antibodies for the treatment of COVID-19 Institute of Microbiology, CAS Shanghai Junshi Biosciences Co. Ltd. Payment unspecified 3/20/20
Zelluna and Karolinska Institute to develop and commercialize T-cell receptor natural killer products for the treatment of patients with solid cancers Karolinska Institute Zelluna Immunotherapy A/S Payment unspecified 3/12/20
Lift Biosciences and King’s College London to develop an induced pluripotent stem cells version of its N1a neutrophil cancer cell therapy product, N-LIfT King’s College London Lift Biosciences Ltd. Payment unspecified 3/26/20
SK Chemicals and KCDC to develop synthetic antigen-based subunit vaccine for COVID-19 Korea Center for Disease Control & Prevention SK Chemicals Co. Ltd. Payment unspecified 3/18/20
Horama to use LUMC's patent and know-how to develop HORA-001 for pathogenic CRB1 gene mutations associated inherited retinal dystrophy worldwide Leiden University Medical Center Horama SA Payment unspecified 3/18/20
Royalty Pharma acquires Massachusetts General Hospital's royalty interest in Entyvio for ulcerative colitis, Crohn's disease and inflammatory bowel disease Massachusetts General Hospital Royalty Pharma $94.00 3/5/20
Medicines Patent to commercialize Medincell's ivermectin against malaria in low- and middle-income countries Medincell SA Medicines Patent Pool Payment unspecified 3/25/20
Mount Sinai and Harbour Biomed to develop biotherapies using H2L2 Harbour Mice platform for cancer and COVID-19 Mount Sinai Health System Harbour Biomed Therapeutics Ltd. Payment unspecified 3/6/20
Gene Techno Science and Nagoya University to develop a therapy against spinal cord injury Nagoya University Gene Techno Science Co. Ltd. Payment unspecified 3/5/20
National Cancer Institute to study safe nanotechnology-based cancer therapeutics using Curadigm's Nanoprimer technology National Cancer Institute Curadigm Payment unspecified 3/9/20
Vir Biotechnology and National Institute of Allergy and Infectious Diseases to research on monoclonal antibodies for coronaviruses, including SARS, MERS and SARS-CoV-2 National Institute of Allergy and Infectious Diseases Vir Biotechnology Inc. Payment unspecified 3/11/20
National Institute of Allergy and Infectious Diseases to evaluate Airway's AT-100 for coronavirus National Institute of Allergy and Infectious Diseases Airway Therapeutics LLC Payment unspecified 3/11/20
NIID to evaluate AIM Immunotech's Ampligen for the treatment of COVID-19 infection National Institute of Infectious Diseases Japan AIM Immunotech Inc. Payment unspecified 3/9/20
NRC and Edesa Biotech to develop immunotherapies and identify the lead candidate for vitiligo and other diseases worldwide National Research Council of Canada Edesa Biotech Inc. Payment unspecified 3/12/20
VBI Vaccines and NRC of Canada to develop a pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS National Research Council of Canada VBI Vaccines Inc. Payment unspecified 3/31/20
Bellus Health to acquire BLU-5937 and P2X3 antagonists IP assets from admare Bioinnovations' Neomed Institute Neomed Institute Bellus Health Inc. Payment unspecified 3/23/20
Netherlands Cancer Institute and Revolution Medicines to conduct phase I/Ib trial on combination of RMC-4630 with an ERK Inhibitor for tumors harboring RAS mutations Netherlands Cancer Institute Revolution Medicines Inc. Payment unspecified 3/9/20
Gene Techno and Oita University to develop therapy for peripheral nerve paralysis Oita University Gene Techno Science Co. Ltd. Payment unspecified 3/5/20
Ology Bioservices to develop, manufacture and deliver monoclonal antibody for Department of Defense to treat COVID-19 virus Ology Bioservices Inc. U.S. Department of Defense $14.00 3/23/20
Osaka University and Anges to develop DNA vaccine for Coronavirus infection using DNA plasmid technology Osaka University Anges MG Inc. Payment unspecified 3/5/20
Eusa Pharma and Papa Giovanni XXIII Hospital to conduct research study on siltuximab for COVID-19 Ospedale Papa Giovanni XXIII Eusa Pharma Payment unspecified 3/18/20
The Rising Tide Foundation and Oxford University Innovation to develop MMD drugs against cancer Oxford University Innovation Rising Tide Foundation $0.30 3/5/20
Parker Institute to evaluate Lonza's Cocoon platform for manufacturing of cell therapies against cancer Parker Institute for Cancer Immunotherapy Lonza Group AG Payment unspecified 3/9/20
Rega Institute to conduct antiviral screening on Johnson & Johnson's compound libraries including vaccine against COVID-19 Rega Institute for Medical Research Johnson & Johnson Payment unspecified 3/30/20
Bridge Medicines and The Rockefeller University to develop ENL-YEATS inhibitors against acute leukemia Rockefeller University Bridge Medicines LLC Payment unspecified 3/16/20
Sabin Vaccine to manufacture Ebola Sudan and Marburg vaccines for VRC Sabin Vaccine Institute National Institute of Allergy and Infectious Diseases $5.30 3/5/20
Exscientia and Scripps Research Institute to screen and identify antiviral drugs against COVID-19 Scripps Research Institute Exscientia Ltd. Payment unspecified 3/31/20
Haihe Biopharma to develop Shanghai Institute of Materia's HH-2853 for non-Hodgkin's lymphoma and advanced solid tumors in the U.S. Shanghai Institute of Materia Medica of the Chinese Academy of Sciences Haihe Biopharma Payment unspecified 3/17/20
Haihe Biopharma to develop Shanghai Institute of Materia Medica of the Chinese Academy of Sciences' SOMCL-18-202 against cancer worldwide Shanghai Institute of Materia Medica of the Chinese Academy of Sciences Haihe Biopharma Payment unspecified 3/18/20
Stanford University to evaluate Lonza's Cocoon platform for manufacturing of cell therapies against cancer Stanford University School of Medicine Lonza Group AG Payment unspecified 3/9/20
Temple University to evaluate anti-viral activity of Can-Fite's piclidenoson on coronaviruses viral load in a mammalian cell model system Temple University Can-Fite Biopharma Ltd. Payment unspecified 3/13/20
LLS to conduct phase I/IIb clinical study of Tolero's dubermatinib for acute myeloid leukemia The Leukemia & Lymphoma Society Tolero Pharmaceuticals Inc. Payment unspecified 3/26/20
Tsinghua University and Brii Biosciences to discover, develop, manufacture and commercialize fully human neutralizing monoclonal antibodies for COVID-19 Tsinghua University Brii Biosciences Ltd. Payment unspecified 3/31/20
VUMC to identify antibodies using Twist Bioscience's antibody drug discovery libraries and synthetic genes for COVID-19 Twist Bioscience Corp. Vanderbilt University Medical Center Payment unspecified 3/26/20
Innovation to enter material transfer agreement with an undisclosed U.S. university to evaluate brilacidin against COVID-19 Undisclosed U.S. university Innovation Pharmaceuticals Inc. Payment unspecified 3/6/20
University hospital Ghen to evaluate Partner Therapeutics' Leukine for the treatment of respiratory illness associated with COVID-19 Universitair Ziekenhuis Gent Partner Therapeutics Inc. Payment unspecified 3/24/20
University of Alberta to conduct a phase I trial for Protokinetix's PKX-001 against type I diabetes University of Alberta Protokinetix Inc. Payment unspecified 3/24/20
Cerus and University of California to optimize convalescent plasma therapy for COVID-19 University of California Cerus Corp. Payment unspecified 3/26/20
Epivax and University of Georgia to develop a coronavirus SARS-CoV-2 vaccine and immunology University of Georgia Epivax Inc. Payment unspecified 3/4/20
CEL-SCI and University of Georgia to develop ligand epitope antigen presentation system COVID-19 immunotherapy University of Georgia CEL-SCI Corp. Payment unspecified 3/23/20
Spherix to use University of Maryland's patents related to methods of treating coronavirus infection University of Maryland Batimore Spherix Inc. Payment unspecified 3/6/20
University of Miami and Heat Biologics to develop a vaccine targeting SARS-CoV-2 coronavirus infection University of Miami Heat Biologics Inc. Payment unspecified 3/5/20
Rising Pharma and University of Minnesota to conduct clinical trial exploring hydroxychloroquine for COVID-19 University of Minnesota Rising Pharma Holdings Inc Payment unspecified 3/27/20
Askbio and UNC to develop and commercialize gene therapy to correct deficiency in UBE3A gene for Angelman syndrome University of North Carolina Asklepios Biopharmaceutical Inc. Payment unspecified 3/18/20
OUHSC and Pure MHC to develop vaccine for COVID-19 University of Oklahoma Health Sciences Center Puremhc LLC Payment unspecified 3/20/20
University of Pittsburgh to support Southwest Research Institute on the synthesis and compound design University of Pittsburgh Southwest Research Institute Payment unspecified 3/24/20
Dynavax and University of Queensland as part of a coalition for epidemic preparedness initiative to develop COVID-19 vaccine University of Queensland Dynavax Technologies Corp. Payment unspecified 3/2/20
CSL and University of Queensland to develop COVID-19 vaccine using MF59 adjuvant platform technology University of Queensland CSL Ltd. Payment unspecified 2/12/20
University of Technology Sydney to sign memorandum of understanding to use Aragen's CHO DG-44 expression system to develop therapeutic antibodies University of Technology Sydney Aragen Bioscience Inc. Payment unspecified 3/3/20
UTMB to conduct research on Moleculin Biotech's WP-1122 against COVID-19 infection University of Texas Medical Branch at Galveston Moleculin Biotech Inc. Payment unspecified 3/17/20
Q2 Solutions and UTMB to develop a novel assay for COVID-19 vaccine test University of Texas Medical Branch at Galveston Q Squared Solutions LLC Payment unspecified 3/24/20
UTMB to test Sorrento’s COVID-19 therapeutics in preclinical phase University of Texas Medical Branch at Galveston Sorrento Therapeutics Inc. Payment unspecified 3/31/20
Respirerx to use UWMRF's patents related to GABA(A) receptor allosteric neuromodulators UWM Research Foundation Inc. Respirerx Pharmaceuticals Inc. Payment unspecified 3/4/20
Immuron and WRAIR to test Travelan against isolates of Shigella, enterotoxigenic Escherichia coli, Vibrio cholerae and Campylobacter jejuni Walter Reed Army Institute of Research Immuron Ltd. Payment unspecified 3/11/20

No Comments